Toes RE - Search Results

1

MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.

Sijts AJ, Standera S, Toes RE, Ruppert T, Beekman NJ, van Veelen PA, Ossendorp FA, Melief CJ, Kloetzel PM. Sijts AJ, et al. Among authors: toes re. J Immunol. 2000 May 1;164(9):4500-6. doi: 10.4049/jimmunol.164.9.4500. J Immunol. 2000. PMID: 10779750

2

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene.

Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. Toes RE, et al. J Immunol. 1995 Apr 1;154(7):3396-405. J Immunol. 1995. PMID: 7534797

3

Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization.

Feltkamp MC, Vierboom MP, Toes RE, Ossendorp F, ter Schegget J, Melief CJ, Kast WM. Feltkamp MC, et al. Among authors: toes re. Immunol Lett. 1995 Jul-Aug;47(1-2):1-8. doi: 10.1016/0165-2478(95)00052-7. Immunol Lett. 1995. PMID: 8537084

4

Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.

Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Toes RE, et al. J Immunol. 1996 May 15;156(10):3911-8. J Immunol. 1996. PMID: 8621930

5

Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.

Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJ. Toes RE, et al. J Immunol. 1998 May 1;160(9):4449-56. J Immunol. 1998. PMID: 9574550

6

Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells.

Schoenberger SP, van der Voort EI, Krietemeijer GM, Offringa R, Melief CJ, Toes RE. Schoenberger SP, et al. Among authors: toes re. J Immunol. 1998 Oct 15;161(8):3808-12. J Immunol. 1998. PMID: 9780143

7

Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells.

Ludewig B, McCoy K, Pericin M, Ochsenbein AF, Dumrese T, Odermatt B, Toes RE, Melief CJ, Hengartner H, Zinkernagel RM. Ludewig B, et al. Among authors: toes re. J Immunol. 2001 Mar 15;166(6):3678-87. doi: 10.4049/jimmunol.166.6.3678. J Immunol. 2001. PMID: 11238607

8

Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.

den Boer AT, Diehl L, van Mierlo GJ, van der Voort EI, Fransen MF, Krimpenfort P, Melief CJ, Offringa R, Toes RE. den Boer AT, et al. Among authors: toes re. J Immunol. 2001 Sep 1;167(5):2522-8. doi: 10.4049/jimmunol.167.5.2522. J Immunol. 2001. PMID: 11509591

9

Importance of CD4(+) T helper cell responses in tumor immunity.

Ossendorp F, Toes RE, Offringa R, van der Burg SH, Melief CJ. Ossendorp F, et al. Among authors: toes re. Immunol Lett. 2000 Sep 15;74(1):75-9. doi: 10.1016/s0165-2478(00)00252-2. Immunol Lett. 2000. PMID: 10996631 Review. No abstract available.

10

Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.

Sutmuller RP, Schurmans LR, van Duivenvoorde LM, Tine JA, van Der Voort EI, Toes RE, Melief CJ, Jager MJ, Offringa R. Sutmuller RP, et al. Among authors: toes re. J Immunol. 2000 Dec 15;165(12):7308-15. doi: 10.4049/jimmunol.165.12.7308. J Immunol. 2000. PMID: 11120866

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

450 results

Search Page